Edition:
United States

Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

4.01USD
28 Jun 2017
Change (% chg)

$0.08 (+2.04%)
Prev Close
$3.93
Open
$3.98
Day's High
$4.03
Day's Low
$3.93
Volume
371,058
Avg. Vol
1,077,538
52-wk High
$7.49
52-wk Low
$3.20

AGEN.O

Chart for AGEN.O

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $341.91
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  AGEN.O Industry Sector
P/E (TTM): -- 240.52 19.05
EPS (TTM): -1.28 -- --
ROI: -62.96 -8.03 -5.05
ROE: -421.78 -10.41 -4.28

BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

* AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

Jun 05 2017

BRIEF-Agenus Q1 loss per share $0.18

* Agenus reports first quarter 2017 financial results and provides corporate update

May 04 2017

BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

* Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

Apr 20 2017

BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

* Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

Apr 05 2017

BRIEF-Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities

* Agenus restructures business to sharpen focus on clinical development of cancer therapies

Mar 30 2017

BRIEF-Incyte and Agenus amend collaboration agreement

* Incyte Corp - amended agreement converts ongoing GITR and ox40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs

Feb 14 2017

BRIEF-Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus

* Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing Source text - http://bit.ly/2lpg9SS Further company coverage:

Feb 09 2017

BRIEF-QVT Financial reports 5.08 pct passive stake in Agenus

* QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing Source text - http://bit.ly/2jHW6OQ Further company coverage:

Feb 03 2017

BRIEF-Agenus files for offering of up to 157,513 shares by selling stockholder

* Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing Source text: (http://bit.ly/2jIMpis) Further company coverage:

Jan 20 2017

BRIEF-Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

* Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

Jan 17 2017

More From Around the Web

Earnings vs. Estimates